Published in Arch Dermatol on August 01, 1997
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother (2002) 1.49
Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother (2005) 1.48
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev (2001) 1.47
Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob Agents Chemother (2002) 1.31
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol (2006) 1.21
Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother (2004) 1.10
Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother (2001) 1.06
Molluscum contagiosum. New insights, new directions. Arch Dermatol (1997) 1.00
Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother (2002) 0.94
Cidofovir Activity against Poxvirus Infections. Viruses (2010) 0.80
Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol (1998) 0.76
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
The interferons. Mechanisms of action and clinical applications. JAMA (1991) 2.68
Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol (2005) 2.46
A comparison of 3 lasers and liquid nitrogen in the treatment of solar lentigines: a randomized, controlled, comparative trial. Arch Dermatol (2000) 2.37
Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet (1995) 2.36
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 2.20
Human herpesvirus 8 DNA sequences in blistering skin from patients with pemphigus. Arch Dermatol (1997) 2.12
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88
Cutaneous and subcutaneous endometriosis. Surgical and hormonal therapy. J Dermatol Surg Oncol (1994) 1.82
A new look at typhoid vaccination. Information for the practicing physician. JAMA (1991) 1.73
A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med (1996) 1.73
A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics (1994) 1.68
Atypical hemolytic-uremic syndrome: a comparison with postdiarrheal disease. J Pediatr (1996) 1.59
Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. J Infect Dis (2000) 1.59
Treatment of chronic urticaria with ketotifen. Arch Dermatol (1997) 1.48
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother (1998) 1.47
An outbreak of lindane-resistant scabies treated successfully with permethrin 5% cream. J Am Acad Dermatol (1991) 1.43
Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol (2003) 1.42
Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era? Pediatrics (2001) 1.40
Verrucous cyst. Arch Dermatol (1991) 1.40
Varicella zoster virus. J Am Acad Dermatol (1999) 1.38
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther (1999) 1.31
Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope (1998) 1.29
Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med (2000) 1.27
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res (1999) 1.24
p53 mutations in basal cell carcinomas. Cancer Res (1992) 1.21
Salmonella isolates from humans in the United States, 1984-1986. MMWR CDC Surveill Summ (1988) 1.19
Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res (1996) 1.15
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis (2007) 1.12
Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med (1997) 1.09
An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol (2000) 1.09
Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol (1988) 1.08
Cholera in Louisiana. Widening spectrum of seafood vehicles. Arch Intern Med (1989) 1.07
Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics (2000) 1.07
Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology. Invest Ophthalmol Vis Sci (1997) 1.03
Human herpesvirus-8: detection of novel herpesvirus-like DNA sequences in Kaposi's sarcoma and other lesions. J Mol Med (Berl) (1995) 1.03
Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope (1998) 1.02
Characterization of endemic strains of Shigella sonnei by use of plasmid DNA analysis and pulsed-field gel electrophoresis to detect patterns of transmission. J Infect Dis (1997) 1.01
Invasive sinonasal disease due to Scopulariopsis candida: case report and review of scopulariopsosis. Clin Infect Dis (1994) 1.00
Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol (1999) 0.99
Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet (1999) 0.98
Human papillomavirus, smoking, and cancer. J Cutan Med Surg (2001) 0.98
Omenn's syndrome and related combined immunodeficiency syndromes: diagnostic considerations in infants with persistent erythroderma and failure to thrive. J Am Acad Dermatol (1991) 0.97
Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis (2006) 0.97
A rare case of disseminated cutaneous zoster in an immunocompetent patient. BMC Fam Pract (2005) 0.97
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis (1990) 0.97
Meningitis due to Ochrobactrum anthropi: an emerging nosocomial pathogen. A report of 3 cases. Pediatr Neurosurg (1997) 0.96
Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch Dermatol (1999) 0.96
Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med (1997) 0.96
Incidence of Epstein-Barr virus in astronaut saliva during spaceflight. Aviat Space Environ Med (1999) 0.96
The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Arch Dermatol (1997) 0.95
Herpesvirus-like DNA sequences in classic Kaposi's sarcomas. J Med Virol (1995) 0.95
The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol (2007) 0.95
Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Transplantation (1999) 0.94
Cholera from raw oysters shipped interstate. JAMA (1987) 0.94
Ochrobactrum anthropi meningitis in pediatric pericardial allograft transplant recipients. J Infect Dis (1996) 0.94
Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis. J Pediatr Surg (1998) 0.94
Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother (1993) 0.94
Monitoring populations for DNA repair deficiency and for cancer susceptibility. Environ Health Perspect (1996) 0.92
Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. Sex Transm Dis (1997) 0.92
Failure of the polymerase chain reaction (PCR) to detect human papilloma virus (HPV) in transitional cell carcinoma of the bladder. Anticancer Res (1993) 0.92
Occurrence of human papillomavirus and p53 gene mutations in Kaposi's sarcoma. Virology (1994) 0.92
Production of interferon gamma messenger RNA by cells of non-immune origin. Cytokine (1995) 0.91
Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis (2001) 0.91
Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection. Am J Obstet Gynecol (1995) 0.91
Zinc-alpha(2)-glycoprotein hinders cell proliferation and reduces cdc2 expression. J Cell Biochem Suppl (2001) 0.91
Detection of human herpesvirus-8 DNA in Kaposi's sarcomas from iatrogenically immunosuppressed patients. J Am Acad Dermatol (1998) 0.90
Recombinant desmoglein 3 has the necessary epitopes to adsorb and induce blister-causing antibodies. J Invest Dermatol (1996) 0.90
Genital warts and their treatment. Clin Infect Dis (1999) 0.90
Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. South Med J (1994) 0.90
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol (2007) 0.90
Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett (2010) 0.89
Strain differences in production of murine interferons. Proc Soc Exp Biol Med (1980) 0.89
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother (2000) 0.89
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis (2001) 0.89
Diminished interferon gamma production may be the earliest indicator of infection with the human immunodeficiency virus. Viral Immunol (1989) 0.88
Development of human papillomavirus type 16 associated squamous cell carcinoma of the scrotum in a patient with Darier's disease treated with systemic isotretinoin. J Urol (1995) 0.88
Iatrogenic contamination of multidose vials in simulated use. A reassessment of current patient injection technique. Arch Dermatol (1990) 0.88
Novel therapy for the treatment of human carcinoid. Ann Surg (1991) 0.88
Verrucous carcinoma of the foot associated with human papillomavirus type 16. J Am Acad Dermatol (2001) 0.88
Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol (1997) 0.87
Nosocomial Legionella pneumonia in the neonate. Pediatrics (1993) 0.87
Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med (1997) 0.87
Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol (1997) 0.87
The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med (1994) 0.86
Benign Leydig cell tumor of the testis associated with human papillomavirus type 33 presenting with the sign of Leser-Trélat. J Urol (1993) 0.86
Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Cancer Lett (1999) 0.86
Bacillus cereus infections among oncology patients at a children's hospital. Am J Infect Control (1999) 0.86
Hemorrhagic bullae associated with Vibrio vulnificus septicemia. Report of two cases. Arch Dermatol (1986) 0.86
Fatal septicemia and bullae caused by non-01 Vibrio cholerae. J Am Acad Dermatol (1993) 0.86
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care (1999) 0.85
Conditioned enhancement of natural killer cell activity, but not interferon, with camphor or saccharin-LiCl conditioned stimulus. J Neurosci Res (1987) 0.85
Hemolytic-uremic syndrome in adolescents. Arch Pediatr Adolesc Med (1997) 0.85
Chromosomal radiosensitivity of lymphocytes from skin cancer-prone patients. Mutat Res (1995) 0.85
Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response. J Med Virol (1993) 0.85
Isoforms of cathepsin D and human epidermal differentiation. Biochimie (1998) 0.85
High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. J Med Virol (1998) 0.85
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Ann Intern Med (1994) 0.85
Clustering of post-diarrheal (Shiga toxin-mediated) hemolytic uremic syndrome in families. Clin Nephrol (2003) 0.85